Alpha Cognition says CONVERGE real-world study shows 79.1% of ZUNVEYL users in long-term care reach therapeutic dose

Bitget2026/10/01 12:31

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Alpha Cognition reported initial results from CONVERGE, an ongoing retrospective real-world evidence analysis in long-term care.
Results have already been presented as initial findings, with additional measures to be analyzed as the dataset expands.
ZUNVEYL users were more likely to reach therapeutic dosing than residents on generic acetylcholinesterase inhibitors, including switch patients.
Medication burden trended lower for ZUNVEYL residents, while it rose for residents receiving pooled generic acetylcholinesterase inhibitors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Cognition Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610010830BIZWIRE_USPR_____20261001_BW616604) on October 01, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Alpha Cognition says CONVERGE real-world study shows 79.1% of ZUNVEYL users in long-term care reach therapeutic dose

You may also like

Crypto prices